Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03457636 · ClinicalTrials.gov registry record · Phase 4
The Use of Oracea and Epiduo Forte in Severe Acne Patients
A Phase 4 study, sponsored by Derm Research, PLLC.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT03457636: Completed Phase 4 study, sponsored by Derm Research, PLLC.
NCT03457636 is a Phase 4 study that has completed, run by Derm Research, PLLC. The registered enrollment target is 22 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03457636, a Phase 4 study, has completed, sponsored by Derm Research, PLLC.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4, 8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline. We will evaluate Investigator Global Assessment (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, adverse events and concomitant medications.
Primary Outcome
The IGA is an assessment by the Investigator to assess the severity of the subject's disease wherein 0=Clear Skin, 1=Almost Clear, 2=Mild Severity, 3=Moderate, 4=Severe, 5=Very Severe. Lower score indicate less severe disease.
Interventions
- DRUG Doxycycline Anhydrous 40 MG
- DRUG Adapalene/Benzoyl Peroxide Gel 0.3-2.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2019-01-04 |
| Phase | Phase 4 |
What the finished NCT03457636 record still lists
NCT03457636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Doxycycline Anhydrous 40 MG is the first listed.
NCT03457636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03457636 about?
NCT03457636 is a clinical study titled "The Use of Oracea and Epiduo Forte in Severe Acne Patients". This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4, 8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline. We will evaluate Investigator Global Assessment (IGA), total lesion count, inflammato...
What is the current status of trial NCT03457636?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2018-03-19. Estimated completion is 2019-01-04.
What interventions are being tested in trial NCT03457636?
The interventions under investigation include: Doxycycline Anhydrous 40 MG (DRUG), Adapalene/Benzoyl Peroxide Gel 0.3-2.5% (DRUG).
Who is sponsoring clinical trial NCT03457636?
This trial is sponsored by Derm Research, PLLC, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03457636's enrollment target sits among peer trials
22 1731st of 2000 higher than 259 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI